This invention is directed to pharmaceutical compositions and methods for treating a disorder or condition selected from the group consisting of depression,
anxiety disorders,
phobias, avoidant personality disorder,
eating disorders, chemical dependencies, Parkinson's diseases, obsessive-compulsive disorder, negative symptoms of
schizophrenia, cognitive dysfunction related to
schizophrenia, premenstrual syndrome, stress-induced incontinence, headache,
neuropathic pain,
chronic pain,
urinary incontinence, post-traumatic stress disorder, chronic stress, acute stress,
fibromyalgia, depression comorbid with
fibromyalgia,
obesity,
migraine and a combination thereof in a
mammal. The methods in one embodiment comprise administering to a
mammal in need of treatment for the disorder or condition: (i) at least one
serotonin reuptake inhibitor or pharmaceutically acceptable salt thereof; (ii) at least one
norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof, wherein the
norepinephrine reuptake inhibitor is selected from the group consisting of Structure II, Structure III, and Structure IV as defined in the specification; and (iii) a pharmaceutically acceptable carrier. The pharmaceutical compositions and methods of the invention are also useful for preventing a relapse associated with one of the foregoing disorders or conditions, and for treating a symptom associated with one of the foregoing disorders or conditions, wherein the symptom is selected from the group consisting of cognitive dysfunctions and somatic complaints.